ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. Show more

Location: Chemin des Aulx 12, Geneve, 1228, Switzerland | Website: www.obseva.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$0.00

Open

$0.00

Volume

N/A

Day Range

$0.00 - $0.00

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

2.02%

Institutional Own.

13.42%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ebopiprant (OBE022) Details Preterm labor	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
YSELTY® (linzagolix) Details Inflammatory disease, Endometriosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
YSELTY® (linzagolix) Details Benign tumor	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.